The start of the end for drug resistant bacteria?

A story on the BBC news website today heralds what may be the start of the end for drug resistant bacteria – and it comes from a Heriot-Watt spin-out company.

Founded in 2000, Aquapharm started life with the PhD research of Andrew Mearns-Spragg, who is the company’s Chief Technology Officer.

Andrew has gone on from Heriot-Watt to achieve significant success, including raising over £10m in equity and grant finance, and winning the Ernst & Young Entrepreneur of the year 2008 in Health Care (Scotland) prize.

To quote from the article:

Aquapharm’s chief scientific officer, Dr Tim Morley, said: “From an initial screening of a small portion of our natural product library we have identified 16 novel compounds belonging to totally novel and diverse chemical classes.

“The most advanced compound AQP-182 has a promising pharmacological and pharmacokinetic profile which is extremely relevant for the treatment of hard to treat resistant bacterial infections.”

Heriot-Watt Spin-Out Companies

Heriot-Watt has spun out a broad range of companies, in a range of fields including engineering, food & drink, marine and manufacturing. You can find a list of our spin-outs here. And if you’re interested in starting your own successful company, like Andrew – why not check out our sister blog which talks about this, at Converge Challenge?

%d bloggers like this: